VX-659 + Tezacaftor + Ivacaftor - A Phase 3 Study of VX-659 Combination Therapy in Subjects With Cystic Fibrosis Heterozygous for the F508del Mutation and a Minimal Function Mutation (F/MF)
Greater Baltimore Medical Center 6535 N. Charles St. Suite 250, MD USA
dinesh@cloudbyz.com (422) 776-6909
